Compare SABS & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SABS | FT |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.4M | 199.8M |
| IPO Year | N/A | N/A |
| Metric | SABS | FT |
|---|---|---|
| Price | $4.14 | $8.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $9.80 | N/A |
| AVG Volume (30 Days) | ★ 502.5K | 56.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.85% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $6.71 |
| 52 Week High | $6.60 | $8.35 |
| Indicator | SABS | FT |
|---|---|---|
| Relative Strength Index (RSI) | 52.96 | 45.65 |
| Support Level | $3.52 | $7.80 |
| Resistance Level | $4.68 | $8.20 |
| Average True Range (ATR) | 0.30 | 0.09 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 36.11 | 31.46 |
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.